Medicus Pharma marks three years with approximately $90M raised, a portfolio anchored by CD228V, FDA authorization for a registrational SkinJect® study and an optimized Teverelix® protocol submitted.   Read more: medicuspharma.com/medicus-ph… $MDCX @R_Bokhari

Medicus Pharma Executive Chairman and CEO Dr. Raza Bokhari joined @ST_BoardroomX host Johny Fernandez to discuss CD228V’s development plans, SkinJect's new focus on Gorlin syndrome and the milestones ahead. youtu.be/zBjbjvKrhpw?is=7out… @R_Bokhari

How can clinicians address cardiovascular risk during prostate cancer treatment? In Cancer Network, $MDCX CMO and Antev Limited, United Kingdom CEO Dr. Faisal Mehmud discusses risk assessment, hormonal therapy choices and the research needed to evaluate Teverelix’s potential cardiovascular differentiation. cancernetwork.com/view/appro… @R_Bokhari

bioworld.com/articles/734442… @R_Bokhari

$MDCX has submitted a proposed Phase 2b/3 protocol for Teverelix® to the FDA. If agreed, the design could reduce planned enrollment in advanced prostate cancer from ~1,500 to ~600 patients. Medicus intends to seek a development partner following FDA feedback.   medicuspharma.com/medicus-ph… @R_Bokhari

On World Cancer Research Day, we honor the Researchers, physicians, patients, caregivers and families advancing the fight against cancer. Needless to state curing cancer requires sustained research, bold collaboration and a shared commitment to turning scientific discoveries into meaningful treatments. The path is challenging, but the urgency is clear: at Medicus we remain resolved to do our part to accelerate progress toward cures in our lifetime. Raza Bokhari, MD Executive Chairman & CEO @R_Bokhari

New commentary from Streetwise Reports examines Medicus Pharma's ($MDCX) evolution into a precision oncology-led biotechnology company, its strategy for advancing CD228V and the potential across its broader pipeline.   Read more: streetwisereports.com/articl… @R_Bokhari

Medicus Pharma is narrowing SkinJect® development to Gorlin syndrome, a rare disorder affecting ~11,000 US patients with recurrent basal cell carcinomas, and ending sporadic BCC development. Its FDA-authorized Phase 2b study is underway.   Read more: medicuspharma.com/medicus-ph… $MDCX @R_Bokhari

Medicus Pharma: Pfizer funded antibody drug conjugate study update - YouTube - goo.gl/alerts/zDZg9Z #GoogleAlerts

Medicus Pharma published an abridged Phase 2 SkinJect® CSR naming the 200 µg patch as the lead dose. The CSR is the foundation for its FDA-authorized Gorlin syndrome study, SKNJCT-005, and for partnership talks on nodular BCC.   Full announcement: medicuspharma.com/medicus-ph… $MDCX @R_Bokhari

Medicus Pharma ($MDCX) is transforming into a precision oncology-led company. CD228V, a second-generation antibody-drug conjugate targeting melanotransferrin/CD228, is now the principal strategic priority, with initial development in relapsed or refractory melanoma.   Read more: medicuspharma.com/medicus-ph… $MDCX   @R_Bokhari

Seeking Alpha covered Medicus Pharma's new licensing agreement with Pfizer for CD228V (PF-08046031), an early clinical-stage ADC targeting CD228. $MDCX   Read more: seekingalpha.com/news/464002… @R_Bokhari

There are currently no approved drugs targeting CD228, a protein highly expressed in melanoma and several other solid tumors. Fierce Biotech covers Medicus Pharma's new agreement with Pfizer to develop CD228V (PF-08046031), an early-stage ADC aimed at changing that. $MDCX   Read the full story: fiercebiotech.com/biotech/pf… @R_Bokhari

RARECast Podcast: Dr. Raza Bokhari, CEO of Medicus Pharma, on Gorlin syndrome, the burden of repeated surgeries for BCC patients and how SkinJect®’s microneedle approach is designed to deliver localized treatment. He also shares Phase 2 clearance data and next steps toward a registrational study.   Listen to the full episode: globalgenes.org/raredaily/fr… $MDCX @R_Bokhari

Dr. Faisal Mehmud, Chief Medical Officer of Medicus Pharma, joins the Life Science Insights 360 Podcast to talk SkinJect®, Teverelix®, cardiovascular safety in oncology drug development, and the growing role of AI in clinical research.   Listen to the full episode: podcasts.apple.com/us/podcas… @R_Bokhari

ICYMI: MyChesCo covered Medicus's FDA “Study May Proceed” letter authorizing the Phase 2b SKNJCT-005 study of SkinJect® in patients with Gorlin Syndrome.   Full story: mychesco.com/a/news/regional… $MDCX @R_Bokhari

MyChesCo covered Medicus's UAE IND authorization for PRECISION-E2, a genomics-guided Phase 2a study of Teverelix® in women with symptomatic endometriosis.   Story here: mychesco.com/a/news/regional… $MDCX @R_Bokhari

Medicus Pharma ($MDCX) names Dr. Faisal Mehmud CEO of Antev Limited, its UK subsidiary, effective August 30. He remains Medicus CMO and Antev Co-Chairman, as Teverelix® advances in prostate cancer, urinary retention and endometriosis.   Read more: medicuspharma.com/medicus-ph… @R_Bokhari

Medicus Pharma ($MDCX) has received UAE Department of Health authorization to proceed with PRECISION-E2. This Phase 2a study evaluates Teverelix® in women with moderate-to-severe endometriosis, serving as one of the first prospective genomics-guided precision medicine programs for the disease.   Read more: medicuspharma.com/medicus-ph… @R_Bokhari

Patients with Gorlin Syndrome may develop dozens—even hundreds—of basal cell carcinomas over their lifetime.   Thanks to Pharma Now for covering Medicus Pharma's FDA-cleared registrational Phase 2b SkinJect® study and its potential to address this significant unmet need.   Read more: pharmanow.live/latest-news/m… $MDCX @R_Bokhari